아세신즈팜(ASND) 주가 전망 및 기업 분석 - PER·배당·실적·목표주가·RSI·MACD

ASND

Ascendis Pharma A/S

7월 27일 2:34 PM ET (한국 7/28 03:34)

$253.86

+1.20 ▲ +0.47%

아세신즈팜(ASND) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시가총액

$15.8B

미드캡

P/E

28.6

적정 수준

배당수익률

없음

52주 위치

77%

저점 +58% · 고점 -10%

애널리스트

적극 매수

B+

Fundamental health

vs. Biotechnology

수익성

Top 9%

성장

Top 30%

밸류에이션

Top 20%

재무 안정

Top 47%

Index ⓘ	-	P/E ⓘ	28.61	EPS (ttm) ⓘ	8.87	Insider Own ⓘ	0.89%	Shs Outstand ⓘ	62.1M	Perf Week ⓘ	-2.74%
Market Cap ⓘ	15.77B	Forward P/E ⓘ	21.52	EPS next Y ⓘ	-26.21%	Insider Trans ⓘ	-3.19%	Shs Float ⓘ	61.6M	Perf Month ⓘ	6.66%
Enterprise Value ⓘ	16.14B	PEG ⓘ	-	EPS next Q ⓘ	1.71	Inst Own ⓘ	101.96%	Short Float ⓘ	5.32%	Perf Quarter ⓘ	12.83%
Income ⓘ	0.58B	P/S ⓘ	15.68	EPS this Y ⓘ	473.69%	Inst Trans ⓘ	-41.48%	Short Ratio ⓘ	4.42	Perf Half Y ⓘ	11.03%
Sales ⓘ	1.01B	P/B ⓘ	28.04	EPS next 5Y ⓘ	-	ROA ⓘ	33.69%	Short Interest ⓘ	3.28M	Perf YTD ⓘ	19.05%
Book/sh ⓘ	9.05	P/C ⓘ	23.89	EPS past 3/5Y ⓘ	27.03% 14.76%	ROE ⓘ	325.8%	52W High ⓘ	-10.03% ($282.15)	Perf Year ⓘ	50.83%
Cash/sh ⓘ	10.63	P/FCF ⓘ	311.79	Sales past 3/5Y ⓘ	147.23% 152.45%	ROIC ⓘ	57.78%	52W Low ⓘ	57.81% ($160.86)	Perf 3Y ⓘ	193.48%
Dividend Est. ⓘ	-	EV/EBITDA ⓘ	1194.7	EPS Y/Y TTM ⓘ	249.36%	Gross Margin ⓘ	87.35%	Volatility(W/M) ⓘ	3.09% 3.59%	Perf 5Y ⓘ	119.49%
Dividend TTM ⓘ	-	EV/Sales ⓘ	16.05	Sales Y/Y TTM ⓘ	155.14%	Oper. Margin ⓘ	-0.66%	ATR (14) ⓘ	8.65	Perf 10Y ⓘ	1861.82%
Dividend Ex-Date ⓘ	-	Quick Ratio ⓘ	0.72	EPS Q/Q ⓘ	787.72%	Profit Margin ⓘ	57.88%	RSI (14) ⓘ	49.52	Recom ⓘ	1.1
Dividend Gr. 3/5Y ⓘ	-	Current Ratio ⓘ	1	Sales Q/Q ⓘ	171.53%	SMA20 ⓘ	-3.79% ($263.86)	Beta ⓘ	0.38	Target Price ⓘ	$303.49
Payout ⓘ	-	Debt/Eq ⓘ	1.84	Earnings ⓘ	2026/5/7	SMA50 ⓘ	4.2% ($243.63)	Rel Volume ⓘ	0.53	Prev Close ⓘ	$252.66
Employees ⓘ	-	LT Debt/Eq ⓘ	0.79	EPS/Sales Surpr. ⓘ	5921.98% -7.6%	SMA200 ⓘ	12.72% ($225.21)	Avg Volume(3M) ⓘ	0.74M	Price ⓘ	$253.86
IPO ⓘ	2015/1/28	Option/Short ⓘ	Yes/Yes			Trades ⓘ	7472	Volume ⓘ	390,400	Change ⓘ	0.47%

Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Ascendis Pharma A/S (ASND) Investment Analysis

What kind of company is Ascendis Pharma A/S?

아세신즈팜(ASND) 초고성장주

Healthcare · Biotechnology

#711 by Market Cap — Mid-Cap

A Denmark-based biopharmaceutical company that develops and sells treatments for rare endocrine disorders, such as growth hormone deficiency, leveraging its proprietary drug delivery technology designed to extend the duration of efficacy.

Learn more about Ascendis Pharma A/S →

Market Cap

$15.8B

Approx. KRW 21.6 trillion

⚖️ 5% of Samsung Electronics

Market Cap Rank711

IPO2015/01/28

Current Price$253.86 ≈ 347,788원

NASD · Denmark

Key Events

⏰ Upcoming events

🔔 Earnings release

The next release date has not been announced yet.

🎯 Ex-dividend date

No scheduled dividends

📜 Recent events

🔔 Earnings release 2026년 5월 7일 (목) · 장 시작 전 EPS +5922.0% 매출 -7.6%

🔔 Earnings release 2026년 2월 11일 (수) · 장 마감 후 EPS -583.2% 매출 +0.8%

Is it profitable?

Profitability weak

Profitability — How efficiently it makes money

Operating Margin

Profit kept from selling products and services (higher is better)

-0.7%

✓ 적자

💡 적자 상태 — 수익을 내지 못하고 있습니다

Net Margin

Share of revenue left after taxes and interest are paid

57.9%

✓ 우수

My positionTop 5%

Low range Average High range

Biotechnology 대형주 Median 8.6% · Top tier

💡 일반적으로 8% 이상이면 양호, 15% 이상이면 우수

Gross Margin

Profit after subtracting raw-material costs only (signals product competitiveness)

87.3%

✓ 양호

My positionMid-range

Low range Average High range

Biotechnology 대형주 Median 86.4% · Top 46%

💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)

ROE

Annual return earned on shareholders' equity (15%+ is strong)

325.8%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 11.9% · Top tier

💡 일반적으로 15% 이상이면 우수 (단, 부채 레버리지 효과 주의)

ROA

Annual earnings relative to total company assets

33.7%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 5.1% · Top tier

💡 일반적으로 5% 이상이면 양호, 10% 이상이면 우수

ROIC

Return generated per dollar invested in the business

57.8%

✓ 우수

My positionTop 5%

Low range Average High range

Healthcare 대형주 Median 7.4% · Top tier

💡 자본비용(보통 8~10%)보다 높으면 가치 창출, 15% 이상이면 우수

Financial health — Debt & liquidity burden

Debt-to-Equity (D/E)

Debt relative to equity (lower is healthier)

1.84

✓ Very high debt

My positionBottom 5%

Low range Average High range

Biotechnology Median 0.05

💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)

Current Ratio

Liquid assets available to cover liabilities due within a year

1.00

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology Median 5.75

💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의

Quick Ratio

Liquid assets excluding inventory, available for immediate use

0.72

✓ 평균

My positionMid-range

Low range Average High range

Biotechnology Median 5.47

💡 1.0 이상이면 안전, 0.5 미만이면 주의

* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook

Positive and negative signals are mixed

애널리스트 목표가

$303.49

현재가 대비 +19.6%

💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균

예상 PER (Forward)

21.52배

💡 내년 예상 EPS 기준. 현재 PER과 비교해 이익 성장 반영 정도 확인

내년 EPS 예상 성장률

-26.2%

💡 10% 이상이면 견조한 성장, 마이너스는 이익 감소 예상

⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Average Earnings Performance

Mixed beats and misses

예상 상회

예상 부합

예상 하회

50%

상회 비율

-76.9%

평균 서프라이즈

2026.05.07

상회

실적 $0.27 · 예상 $-0.08 +429.3%

2026.02.11

하회

-583.2%

💡 예상보다 높은 실적을 자주 내는 기업은 실적 신뢰도가 높다고 평가됩니다. 단, 애널리스트 기대치가 낮게 설정되었을 수도 있으니 절대 수치도 함께 봐야 합니다.

Is it growing?

Average Growth

Mid-range within the industry

Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile

🔮 How much will it grow? (analyst forecasts)

This Year's EPS Outlook

Projected EPS growth rate for this year

+473.7%

우수

My positionTop 5%

Low range Average High range

초고성장주 대형주 Median 47.1% · Top tier

Next Year's EPS Outlook

Projected EPS growth rate for next year (analyst consensus)

-26.2%

매우 부진

My positionBottom 5%

Low range Average High range

초고성장주 대형주 Median 32.1% · Bottom tier

📊 How much has it grown? (actual results)

Past 3-Year EPS

Actual average annual EPS growth over the past 3 years

+27.0%

양호

My positionMid-range

Low range Average High range

초고성장주 대형주 Median 1.0% · Top 33%

Past 5-Year EPS

Actual average annual EPS growth over the past 5 years

+14.8%

양호

My positionMid-range

Low range Average High range

초고성장주 대형주 Median 11.8% · Top 46%

Past 5-Year Revenue

How much revenue grew over the past 5 years

+152.4%

우수

My positionTop 5%

Low range Average High range

초고성장주 대형주 Median 28.9% · Top tier

⚡ Short-term momentum

QoQ Revenue

Revenue change from the previous quarter (short-term momentum)

+171.5%

우수

My positionTop 5%

Low range Average High range

초고성장주 대형주 Median 25.3% · Top tier

* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

New to investing terms? Look it up in the financial dictionary →

Has the stock risen over the long term?

Outperformed the market by 52%p over 5 years

ASND +119.5% · S&P 500 +68.0%

Excess return vs. market (price-based, ex-dividends)

5-year basis

vs S&P 500

+51.5%p

well ahead of the market

vs Health Care (XLV)

+95.8%p

well ahead of the sector average

1-year basis

vs S&P 500

+34.4%p

well ahead of the market

vs Health Care (XLV)

+31.1%p

well ahead of the sector average

Rank among peers

5-year return Upper-Mid (38%) Based on 24 peers

1-year return Upper-Mid (45%) Based on 24 peers

Current position within 52-week range

Low (-57.8%p) High (-10.0%p)

Current price is 57.8% above the 52-week low and 10.0% below the 52-week high

Recent risk (last 120 trading days)

Max drawdown

-17.7%

Annualized volatility

38.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

close
BB Upper
BB Mid
BB Lower
Tenkan
Kijun
Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴

Current diagnosis · 2026-07-24

Downtrend zone

Current price $253.86 below the midline ($263.86). Normal downward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟡

Current diagnosis · 2026-07-24

Neutral zone — weak trend

MACD 2.969 · Signal 6.018 · Hist -3.049. Weak directional bias.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔴

Current diagnosis · 2026-07-24

Bearish zone

RSI 49.5 (below the neutral level of 50). Selling pressure leads, indicating a weak trend. Stoch %K is also 12.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry

Cheap on Vs. Earnings, Pricey on Vs. Assets·Vs. Sales·Vs. Cash Flow

💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.

💵 Vs. Earnings Cheap

🏢 Vs. Assets Pricey

🧾 Vs. Sales Pricey

💧 Vs. Cash Flow Pricey

💵 Vs. Earnings

PER Price-to-Earnings Ratio

How expensive the price is vs. earnings — lower is cheaper

28.61x

✓ Fair

My positionMid-range

Low range Average High range

Biotechnology median 15.34x · Around the industry average

💡 PER 15 이하 저평가, 25 이상이면 성장성 검증 필요 (적자 기업은 의미 없음)

💵 Vs. Earnings

Forward PER Forward Price-to-Earnings Ratio

PER using next year's estimated earnings — reflects growth

21.52x

✓ Cheap

My positionMid-range

Low range Average High range

Biotechnology 대형주 median 22.38x · Around the industry average

💡 향후 12개월 예상 EPS 기준 PER. 현재 PER보다 낮으면 이익 성장 중

🏢 Vs. Assets

PBR Price-to-Book Ratio

Price vs. the company's asset value — below 1 trades cheaper than assets

28.04x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 대형주 median 7.26x · Bottom 16% — expensive within the industry

💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)

🧾 Vs. Sales

PSR Price-to-Sales Ratio

Market cap vs. revenue — lower is cheaper relative to sales

15.68x

✓ Pricey

My positionBottom 25%

Low range Average High range

Biotechnology 대형주 median 9.45x · Bottom 24% — expensive within the industry

💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)

💧 Vs. Cash Flow

EV/EBITDA Enterprise Value Multiple

Total enterprise value ÷ operating cash earnings — a benchmark for M&A

1194.70x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Biotechnology median 22.58x · Bottom 1% — expensive within the industry

💡 EV/EBITDA 10 이하 저평가, 20 이상이면 고평가 (M&A 밸류 기준)

💧 Vs. Cash Flow

P/FCF Price-to-Free-Cash-Flow Ratio

Price vs. actual cash generation — lower means more efficient

311.79x

✓ Very pricey

My positionBottom 5%

Low range Average High range

Biotechnology median 18.43x · Bottom 1% — expensive within the industry

💡 P/FCF 20 이하면 현금창출 대비 저평가 (실질 수익성 기준)

Analyst target price (reference)

$303.49 vs. current price +19.6%

* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.

As of: Recent snapshot · Peer group: Biotechnology

Who owns it?

Ownership flow shows some pressure

Insider modest net selling -3.2% · Institutional net selling -41.5% · Short interest moderate 5.3% · Short interest fell -1.0%p over the last 89 days

📈 Recent trading flow (6 months)

🧑‍💼 Insiders (executives & directors)

-3.2%

Insiders net selling

🏦 Institutions (funds & investors)

-41.5%

Institutions large net selling

💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.

👥 Holdings composition

🏦 Institutions 102.0%

Institution-led, stable structure

Healthcare 대형주 Median 91.9%

🧑‍💼 Insiders 0.9%

Low, common among large-caps

Healthcare 대형주 Median 0.8%

👤 Retail investors (estimated) 0.0%

Everyone excluding institutions and insiders

Institutions Insiders Retail (est.)

📉 Short-selling metrics

Short ratio

5.3%

Moderate

Healthcare 대형주 Median 3.6%

Past 89 days 📉 -1.0%p decrease

Short interest days to cover

4.4 days

Days needed to close short positions using average trading volume

🧮 Share count

Total shares outstanding 62.1M주

Float (tradable shares) 61.6M주

* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 89 days.

ETFs holding ASND

ETFs with the highest weightings · 10 total shown

MEDI

Harbor Health Care ETF

15.56%

$42M

AFOS

ARS Focused Opportunity Strategy ETF

3.64%

$289M

FDG

American Century Focused Dynamic Growth ETF

3.10%

$388M

AADR

AdvisorShares Dorsey Wright ADR ETF

2.91%

$39M

FMED

Fidelity Disruptive Medicine ETF

2.11%

$46M

* Based on official quarterly filings. Latest disclosure; actual current weights may differ.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)

Sorted by market cap, largest first

Stock	Market Cap	PER	PBR	ROE	Dividend Yield	Change
ASND This Stock	$15.8B	28.6 ▼	28.0 ▼	325.8% ▲	-	+0.5%
LLY	$1.13T	43.0 ▼	36.2 ▼	107.64% ▲	0.58% ▼	+0.9%
JNJ	$634.1B	30.5 ▼	7.5 ▼	25.74% ▲	2.04% ▲	+1.6%
ABBV	$458.2B	127.9 ▼	-	15221.82% ▲	2.65% ▲	+0.9%
UNH	$382.1B	27.1 ▼	3.9 ▼	12.49% ▲	2.15% ▲	-0.7%
MRK	$323.7B	36.9 ▼	7.1 ▼	18.97% ▲	2.49% ▲	+0.5%
Sector Avg	-	25.8	2.7	-48.83%	1.25%	-

FAQ

What kind of company is 아세신즈팜(ASND)?

아세신즈팜(ASND) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of ASND?

The market cap of ASND is approximately $15.8B, ranking 711 within its sector.

What is the P/E ratio of ASND?

ASND has a P/E ratio of approximately 28.6x, which can be used to assess its valuation relative to the Healthcare sector average.

What is the 52-week high and low for ASND?

ASND has recorded a 52-week high of $282.15 and a low of $160.86.

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.